Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system

Anna Truini, Angela Alama, Maria Giovanna Dal-Bello, Simona Coco, Irene Vanni, Erika Rijavec, Carlo Genova, Giulia Barletta, Federica Biello, Francesco Grossi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that might represent an important biomarker in lung cancer. The prognosis of patients diagnosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences have reported that tumor aggressiveness is associated with the presence of CTCs in the blood stream; therefore several studies have focused their attention on CTC isolation, characterization and clinical significance. So far the CellSearch® 37 system is the only approach approved by FDA for metastatic breast, prostate and colorectal cancer intended to detect CTCs of epithelial origin in whole blood and to assess prognosis. To date no specific biomarkers have been validated in lung cancer and the identification of novel tumor markers such as CTCs might highly contribute to lung cancer prognosis and management. In the present review the significance of CTC detection in lung cancer is examined through the analysis of the published studies in both non-small cell and small cell lung cancers; additionally the prognostic and the clinical role of CTC enumeration in treatment monitoring will be reported and discussed.

Original languageEnglish
Article numberArticle 242
JournalFrontiers in Oncology
Volume4 AUG
DOIs
Publication statusPublished - 2014

Fingerprint

Circulating Neoplastic Cells
Lung Neoplasms
Biomarkers
Cell Separation
Delayed Diagnosis
Small Cell Lung Carcinoma
Tumor Biomarkers
Colorectal Neoplasms
Neoplasms
Prostatic Neoplasms
Breast Neoplasms

Keywords

  • Biomarker
  • Circulating tumor cells
  • CTC
  • Lung cancer
  • Predictive marker
  • Prognostic marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system. / Truini, Anna; Alama, Angela; Dal-Bello, Maria Giovanna; Coco, Simona; Vanni, Irene; Rijavec, Erika; Genova, Carlo; Barletta, Giulia; Biello, Federica; Grossi, Francesco.

In: Frontiers in Oncology, Vol. 4 AUG, Article 242, 2014.

Research output: Contribution to journalArticle

Truini, A, Alama, A, Dal-Bello, MG, Coco, S, Vanni, I, Rijavec, E, Genova, C, Barletta, G, Biello, F & Grossi, F 2014, 'Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system', Frontiers in Oncology, vol. 4 AUG, Article 242. https://doi.org/10.3389/fonc.2014.00242
Truini, Anna ; Alama, Angela ; Dal-Bello, Maria Giovanna ; Coco, Simona ; Vanni, Irene ; Rijavec, Erika ; Genova, Carlo ; Barletta, Giulia ; Biello, Federica ; Grossi, Francesco. / Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system. In: Frontiers in Oncology. 2014 ; Vol. 4 AUG.
@article{c0946e1bf8a64291b3185c9b4a460a1c,
title = "Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system",
abstract = "Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that might represent an important biomarker in lung cancer. The prognosis of patients diagnosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences have reported that tumor aggressiveness is associated with the presence of CTCs in the blood stream; therefore several studies have focused their attention on CTC isolation, characterization and clinical significance. So far the CellSearch{\circledR} 37 system is the only approach approved by FDA for metastatic breast, prostate and colorectal cancer intended to detect CTCs of epithelial origin in whole blood and to assess prognosis. To date no specific biomarkers have been validated in lung cancer and the identification of novel tumor markers such as CTCs might highly contribute to lung cancer prognosis and management. In the present review the significance of CTC detection in lung cancer is examined through the analysis of the published studies in both non-small cell and small cell lung cancers; additionally the prognostic and the clinical role of CTC enumeration in treatment monitoring will be reported and discussed.",
keywords = "Biomarker, Circulating tumor cells, CTC, Lung cancer, Predictive marker, Prognostic marker",
author = "Anna Truini and Angela Alama and Dal-Bello, {Maria Giovanna} and Simona Coco and Irene Vanni and Erika Rijavec and Carlo Genova and Giulia Barletta and Federica Biello and Francesco Grossi",
year = "2014",
doi = "10.3389/fonc.2014.00242",
language = "English",
volume = "4 AUG",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system

AU - Truini, Anna

AU - Alama, Angela

AU - Dal-Bello, Maria Giovanna

AU - Coco, Simona

AU - Vanni, Irene

AU - Rijavec, Erika

AU - Genova, Carlo

AU - Barletta, Giulia

AU - Biello, Federica

AU - Grossi, Francesco

PY - 2014

Y1 - 2014

N2 - Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that might represent an important biomarker in lung cancer. The prognosis of patients diagnosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences have reported that tumor aggressiveness is associated with the presence of CTCs in the blood stream; therefore several studies have focused their attention on CTC isolation, characterization and clinical significance. So far the CellSearch® 37 system is the only approach approved by FDA for metastatic breast, prostate and colorectal cancer intended to detect CTCs of epithelial origin in whole blood and to assess prognosis. To date no specific biomarkers have been validated in lung cancer and the identification of novel tumor markers such as CTCs might highly contribute to lung cancer prognosis and management. In the present review the significance of CTC detection in lung cancer is examined through the analysis of the published studies in both non-small cell and small cell lung cancers; additionally the prognostic and the clinical role of CTC enumeration in treatment monitoring will be reported and discussed.

AB - Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that might represent an important biomarker in lung cancer. The prognosis of patients diagnosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences have reported that tumor aggressiveness is associated with the presence of CTCs in the blood stream; therefore several studies have focused their attention on CTC isolation, characterization and clinical significance. So far the CellSearch® 37 system is the only approach approved by FDA for metastatic breast, prostate and colorectal cancer intended to detect CTCs of epithelial origin in whole blood and to assess prognosis. To date no specific biomarkers have been validated in lung cancer and the identification of novel tumor markers such as CTCs might highly contribute to lung cancer prognosis and management. In the present review the significance of CTC detection in lung cancer is examined through the analysis of the published studies in both non-small cell and small cell lung cancers; additionally the prognostic and the clinical role of CTC enumeration in treatment monitoring will be reported and discussed.

KW - Biomarker

KW - Circulating tumor cells

KW - CTC

KW - Lung cancer

KW - Predictive marker

KW - Prognostic marker

UR - http://www.scopus.com/inward/record.url?scp=84906503848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906503848&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00242

DO - 10.3389/fonc.2014.00242

M3 - Article

AN - SCOPUS:84906503848

VL - 4 AUG

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 242

ER -